clinical trial · NCT00424866
FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease
Venturis Therapeutics, Inc.·phase2·not yet recruiting·n = 24
Peripheral Arterial DiseaseStenosisIntermittent ClaudicationFGF-1Placebo
brief summary
FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.
started
Oct 15, 2028
primary completion
Feb 5, 2030
completion
Dec 15, 2030
last updated
Aug 19, 2026
detailed description
FGF-1 administered by intramuscular injection for the treatment of peripheral arterial disease with intermittent claudication. Eligible patients are allocated to one of three treatment arms. Patients within each dosing group will be randomized between study drug and vehicle control. Safety, pharmacokinetics, and cardiovascular improvement will be evaluated at day 1 and weeks 1, 4 and 12 post dosing.
official title
A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol